National Guideline on the Management of Vulvovaginal Candidiasis

Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases)

Causative Agent(s)
*Candida albicans* 80-92%
Non-*albicans* species e.g. *C. glabrata*

Clinical Features
The clinical symptoms caused by *albicans* and non-*albicans* species are indistinguishable.

- **Symptoms**
  - Vulval itching
  - Vulval soreness
  - Vaginal discharge
  - Superficial dyspareunia
  - External dysuria

- **Signs**
  - Erythema
  - Fissuring
  - Discharge, may be curdy (non-offensive)
  - Satellite lesions
  - Oedema

None of these symptoms or signs is specific for the diagnosis of candidiasis’. Candidiasis is often diagnosed on the basis of clinical features alone and as many as half of these women may have other conditions e.g. allergic reactions. (Level of evidence:II. *Grade A*).

NB. 10-20% women during reproductive years may harbour *Candida species* in the absence of symptoms. These women do not require treatment.

Diagnosis

- **Clinical**
  - Symptoms/signs non-specific (see above)

- **Investigations**
  - pH of vaginal fluid 4.0-4.5 (pH >5 suspect bacterial vaginosis/trichomoniasis)

- **Microscopy**
  - Gram stain of vaginal discharge collected from anterior fornix or lateral vaginal wall looking for spores/pseudohyphae
  - May detect 65-68% of symptomatic cases

  - Saline microscopy of vaginal discharge collected from anterior fornix or lateral vaginal wall looking for pseudohyphae
  - Sensitivity 40-60%
10% potassium hydroxide (KOH) microscopy of vaginal discharge collected from anterior fornix or lateral vaginal wall looking for pseudohyphae
Sensitivity 70%
NB KOH is toxic to T. vaginalis.

Latex agglutination slide technique of vaginal discharge collected from anterior fornix or lateral vaginal wall using polyclonal antibodies against Candida species. This confers no benefit over microscopy.

Culture
Sabouraud’s media
This should be considered in all symptomatic cases where microscopy is inconclusive or identification of the species would be helpful eg multiple previous treatments, concern re speciation. Level of evidence:IV. Grade C

Management

General advice
Avoid local irritants e.g. perfumed products
Avoid tight fitting synthetic clothing
Level of evidence:IV. Grade C

Treatment
All topical and oral azole therapies give an 80-95% clinical and mycological cure rate in acute vulvo-vaginal candidiasis in non-pregnant women. Nystatin preparations give a 70-90% cure rate under these circumstances. Level of evidence:II. Grade A

Topical Therapies

<table>
<thead>
<tr>
<th>DRUG</th>
<th>FORMULATION</th>
<th>DOSAGE REGIMEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clotrimazole*</td>
<td>Pessary</td>
<td>500mg stat</td>
</tr>
<tr>
<td>Clotrimazole*</td>
<td>Pessary</td>
<td>200mg x 3 nights</td>
</tr>
<tr>
<td>Clotrimazole*</td>
<td>Pessary</td>
<td>100mg x 6 nights</td>
</tr>
<tr>
<td>Clotrimazole*</td>
<td>Vaginal cream (10%)</td>
<td>5g stat</td>
</tr>
<tr>
<td>Econazole**</td>
<td>Pessary (Ecostatin 1)</td>
<td>150mg stat</td>
</tr>
<tr>
<td>Econazole**</td>
<td>Pessary</td>
<td>150mg x 3 nights</td>
</tr>
<tr>
<td>Fenticonazole**</td>
<td>Pessary</td>
<td>600mg stat</td>
</tr>
<tr>
<td>Fenticonazole**</td>
<td>Pessary</td>
<td>200mg x 3 nights</td>
</tr>
<tr>
<td>Isoconazole*</td>
<td>Vaginal tablet</td>
<td>300mg x 2 stat</td>
</tr>
<tr>
<td>Miconazole**</td>
<td>Ovule</td>
<td>1.2g stat</td>
</tr>
<tr>
<td>Miconazole**</td>
<td>Pessary</td>
<td>100mg x 14 nights</td>
</tr>
<tr>
<td>Nystatin</td>
<td>Vaginal cream (100,000 units)</td>
<td>4g x 14 nights</td>
</tr>
<tr>
<td>Nystatin</td>
<td>Pessary (100,000 units)</td>
<td>1-2 x 14 nights</td>
</tr>
</tbody>
</table>

NB * Effect on latex condoms and diaphragms not known
** Product damages latex condoms and diaphragms
Oral Therapies

<table>
<thead>
<tr>
<th>DRUG</th>
<th>FORMULATION</th>
<th>DOSAGE REGIMEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluconazole</td>
<td>Capsule</td>
<td>150mg stat</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Capsule</td>
<td>200mg bd x 1d</td>
</tr>
</tbody>
</table>

NB Avoid in pregnancy/risk of pregnancy and breast feeding
See BNF

Level of evidence: II, Grade A\textsuperscript{6,7,8}

Pregnancy
Asymptomatic colonisation with \textit{Candida species} is higher in pregnancy (30-40%). Symptomatic candidosis is more prevalent throughout pregnancy. Treatment with topical azoles is recommended. Longer courses may be necessary. Oral therapy is contraindicated. Level of evidence:II. Grade B\textsuperscript{7,10}

Sexual Partner(s)
There is no evidence to support treatment of asymptomatic male sexual partners. Level of evidence:I. Grade A\textsuperscript{11}

Follow Up
Unnecessary if symptoms resolve. Test of cure is unnecessary.

Recurrent Candidosis

\textbf{Definition}
Four or more episodes of symptomatic candidosis annually\textsuperscript{9}.

\textbf{Prevalence}
<5% of healthy women of reproductive years.

\textbf{Pathogenesis}
Poorly understood
Exclude diabetes \textit{mellitus}
\textit{Association with recent cunnilingus}\textsuperscript{12}
Other risk factors include underlying immunodeficiency, corticosteroid use, frequent antibiotic use

\textbf{Treatment}
Regimens in current usage are empirical and are not based on randomised controlled trials. Principles of therapy include induction followed by a maintenance regime for 6 months. Cessation of therapy may result in relapse in at least 50% of women.

\textbf{Regimes}
Fluconazole 100mg weekly x 6 months
Clotrimazole pessary 500mg weekly x 6 months
Itraconazole 400mg monthly x 6 months
[Ketoconazole 100mg daily x 6 months
NB: Low risk of idiosyncratic drug induced hepatitis. Monitor LFT's monthly].

Level of evidence:II. Grade B\textsuperscript{5,6,9,13}

Caution: Anecdotal reports of oral contraceptive failure with prolonged oral azole therapy

Auditable Outcome Measures

- Offer microscopy/culture to all women with symptoms suggestive of vulvo-vaginal candidiasis. Target - 100%.

- Initial diagnosis by microscopy of symptomatic culture proven vulvo-vaginal candidiasis in non-pregnant women. Target - 50-60%.

- Cheapest acceptable topical/oral treatment option to be used in non-pregnant women. Target - 80%.

- Asymptomatic male partners should not be treated. Target - 100%.

Acknowledgements

We wish to thank the following for their valuable contribution to this guideline:
Members of the North Thames Audit Group in Genitourinary Medicine

Authors and Centres

David Daniels, West Middlesex University Hospital Trust
Greta Forster, Barts & the London NHS Trust

Membership of the CEG

Clinical Effectiveness Group: Keith Radcliffe (MSSVD); Imme Ahmed (AGUM); Jan Welch (MSSVD); Mark FitzGerald (AGUM); Janet Wilson (Royal College of Physicians GU Medicine Committee).

Conflict of Interest

None

Evidence Base

MEDLINE search-keywords:-vulvo-vaginal candidiasis, vaginal candidosis (1980-2000)
English language only

COCHRANE LIBRARY search-keywords:-vulvo-vaginal candidiasis, vaginal candidosis (2000)
REFERENCES

1. Eckert LO, Hawes SE, Stevens CE, Koutsyl LA, Eschenbach DA, Holmes KK
Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm
Obstet Gynecol 1998; 92:757-765

2. Berg AO, Heidrich FE, Fihn SD et al
Establishing the cause of genitourinary symptoms in women in a family practice:
comparison of clinical examination and comprehensive microbiology
JAMA 1984;251:620-5

Sampling for vaginal candidiasis: how good is it?
Int J STD AIDS 1994;5:356-8

4. Sonnex C, Lefort W
Microscopic features of vaginal candidiasis and their relation to symptomatology
Sex Transm Infect 1999;75:417-419

5. Sobel JD
Vaginitis
N Engl J Med 1997;337:1896-1903

Treatment options for vulvovaginal candidiasis:1993

7. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal
imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)

8. Odds FC
Candidosis of the Genitalia
In Odds FC, Ed. Candida and Candidosis: a Review and Bibliography. 2nd ed.

9. CDC
1998 Guidelines for the Treatment of Sexually Transmitted Diseases
MMWR 1998;47:RR-1 pp75-79

10. Young GL, Jewell D
Topical treatment for vaginal candidiasis in pregnancy

11. Bisschop MP, Merkus JM, Scheygrond H, van Cutsen J
Co-treatment of the male partner in vaginal candidiasis: a double blind randomized
control study
Br J Obstet Gynecol 1986;93:79-81

12. Hellberg D, Zdolsek B, Nilssion S, Mardh PA
Sexual behaviour of women with repeated episodes of vulvovaginal candidiasis

13. Spinollo A, Colonna L, Piazzi G et al
Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole
J Reprod Med 1997;42:83-87